Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001111
Filing Date
2025-05-08
Accepted
2025-05-08 16:06:23
Documents
69
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cldx-20250331x10q.htm   iXBRL 10-Q 1141745
2 EX-31.1 cldx-20250331xex31d1.htm EX-31.1 11504
3 EX-31.2 cldx-20250331xex31d2.htm EX-31.2 11493
4 EX-32.1 cldx-20250331xex32d1.htm EX-32.1 7131
  Complete submission text file 0001410578-25-001111.txt   5699720

Data Files

Seq Description Document Type Size
5 EX-101.SCH cldx-20250331.xsd EX-101.SCH 36092
6 EX-101.CAL cldx-20250331_cal.xml EX-101.CAL 40839
7 EX-101.DEF cldx-20250331_def.xml EX-101.DEF 152334
8 EX-101.LAB cldx-20250331_lab.xml EX-101.LAB 351381
9 EX-101.PRE cldx-20250331_pre.xml EX-101.PRE 252743
72 EXTRACTED XBRL INSTANCE DOCUMENT cldx-20250331x10q_htm.xml XML 1066552
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 25925986
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)